Acadia and Anovo Partner to Transform Rett Syndrome Care
October 3, 2023
Acadia Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders. With a focus on discovering, developing, and commercializing small molecule drugs, Acadia tackles some of the most challenging issues in neuroscience to provide innovative solutions to individuals in need.
What is Rett Syndrome?
Rett Syndrome is a rare and severe neurological disorder that predominantly affects females. Characterized by developmental regression, loss of speech and hand use, repetitive hand movements, seizures, and breathing irregularities, Rett Syndrome profoundly impacts the lives of affected individuals and their families. Despite its rarity, Rett Syndrome poses significant challenges, highlighting the urgent need for effective treatments to alleviate symptoms and improve quality of life.
Acadia Pharmaceuticals, Inc. Partners with Anovo
Our collaboration with Acadia Pharmaceuticals, Inc. represents a significant milestone in addressing the complexities of Rett Syndrome and providing support to individuals and families affected by this condition. We’re proud to provide crucial patient services through Acadia Connect. This platform ensures seamless access to DAYBUE™ (trofinetide), Acadia’s groundbreaking treatment for Rett syndrome.
As the exclusive distributor and specialty pharmacy for DAYBUE, we’re also uniquely positioned to deliver care and support tailored to the needs of patients and their caregivers. Together with Acadia Pharmaceuticals, Inc., we are dedicated to making a meaningful difference in the lives of individuals affected by Rett Syndrome.
Related Posts
Cycle Pharmaceuticals and Anovo Deliver Relief to Those with Homozygous Cystinuria
Cycle Pharmaceuticals was founded in 2012 with one mission in mind: delivering best-in-class drug treatments and services to the underserved…
July 29, 2024
Advancing Rare Disease Care: Insights from the World Orphan Drug Congress and AAN Annual Meeting
The World Orphan Drug Congress (WODC) and the American Academy of Neurology (AAN) Annual Meeting are where healthcare leaders, advocates,…
June 11, 2024
Pyros and Anovo Partner to Elevate Care for Infantile Spasms
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™…
April 1, 2024
